India’s Pharma Giants Eye $90 Billion US Biosimilars Jackpot as FDA Slashes Development Costs
The global pharmaceutical landscape is witnessing a seismic shift, and Indian drugmakers are positioned at its epicentre. As the US biosimilars market prepares to quadruple from $22.6 billion in 2025 to a staggering $90 billion by 2034, a revolutionary FDA draft guideline has thrown open the gates for Indian manufacturers. By potentially halving development costs […]








